{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yau TM"],"funding":["NHLBI NIH HHS","CIHR"],"pagination":["1176-1186"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6439694"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["321(12)"],"pubmed_abstract":["<h4>Importance</h4>Left ventricular assist device (LVAD) therapy improves myocardial function, but few patients recover sufficiently for explant, which has focused attention on stem cells to augment cardiac recovery.<h4>Objective</h4>To assess efficacy and adverse effects of intramyocardial injections of mesenchymal precursor cells (MPCs) during LVAD implant.<h4>Design, setting, and participants</h4>A randomized phase 2 clinical trial involving patients with advanced heart failure, undergoing LVAD implant, at 19 North American centers (July 2015-August 2017). The 1-year follow-up ended August 2018.<h4>Interventions</h4>Intramyocardial injections of 150 million allogeneic MPCs or cryoprotective medium as a sham treatment in a 2:1 ratio (n = 106 vs n = 53).<h4>Main outcomes and measures</h4>"],"journal":["JAMA"],"pubmed_title":["Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial."],"pmcid":["PMC6439694"],"funding_grant_id":["U01 HL088942"],"pubmed_authors":["Maltais S","Gelijns AC","Jeffries N","Rose EA","Yau TM","Soltesz EG","Marks ME","O'Sullivan KL","Parides MK","Miller MA","Acker MA","Hung J","Lala A","Mancini DM","Milano CA","McGowan LK","Taddei-Peters WC","Moquete EG","O'Gara PT","Charbonneau E","Woo YJ","Bagiella E","Pagani FD","Moskowitz AJ","Kern JA","Pan S","Green C","Cardiothoracic Surgical Trials Network","Chang HL","Weisel RD","Selzman CH"],"additional_accession":[]},"is_claimable":false,"name":"Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial.","description":"<h4>Importance</h4>Left ventricular assist device (LVAD) therapy improves myocardial function, but few patients recover sufficiently for explant, which has focused attention on stem cells to augment cardiac recovery.<h4>Objective</h4>To assess efficacy and adverse effects of intramyocardial injections of mesenchymal precursor cells (MPCs) during LVAD implant.<h4>Design, setting, and participants</h4>A randomized phase 2 clinical trial involving patients with advanced heart failure, undergoing LVAD implant, at 19 North American centers (July 2015-August 2017). The 1-year follow-up ended August 2018.<h4>Interventions</h4>Intramyocardial injections of 150 million allogeneic MPCs or cryoprotective medium as a sham treatment in a 2:1 ratio (n = 106 vs n = 53).<h4>Main outcomes and measures</h4>","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-05-03T15:54:22.589Z","creation":"2019-10-11T07:01:04Z"},"accession":"S-EPMC6439694","cross_references":{"pubmed":["30912838"],"doi":["10.1001/jama.2019.2341"]}}